Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

1420006

USP

Levodopa Related Compound B

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

DL-3-O-Methyldopa, 3-Methoxytyrosine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H13NO4
Número de CAS:
7636-26-2
Peso molecular:
211.21
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levodopa

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)

InChI key

PFDUUKDQEHURQC-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Levodopa
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Thomas Müller et al.
Clinical neuropharmacology, 36(2), 52-54 (2013-03-19)
Levodopa (LD)/dopa decarboxylase inhibitor application increases 3-O-methyldopa (3-OMD) concentrations in association with methyl group transfers, which demand for the conversion of methionine to homocysteine. This accompanying reaction is partially reversible by methyl group-donating vitamins. The objective of this study was
Christoph Saxer et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 802(2), 299-305 (2004-03-17)
A simple and rapid assay is described for the simultaneous analysis of levodopa (l-DOPA) and 3-O-methyldopa (3-OMD) in human plasma samples, applying an ion-pair reversed-phase liquid chromatographic method with electrochemical detection, designed for clinical trials performed to study the effect
T Müller et al.
Journal of neural transmission (Vienna, Austria : 1996), 114(3), 347-350 (2006-08-26)
Levodopa (LD) application improves motor symptoms in patients with Parkinson's disease (PD) patients. Little is known on further effects of LD, which induced lower plasma levels of cortisol and lower serotonergic activity in certain brain areas of fish. Objectives of
Manuel Vaz-da-Silva et al.
Drugs in R&D, 9(6), 435-446 (2008-11-08)
Levodopa is the most effective symptomatic treatment for Parkinson's disease (PD), but its use is often associated with development of motor complications. These adverse responses to fluctuations in dopaminergic stimulation can be reduced by concomitant administration of a catechol-O-methyltransferase (COMT)
Teresa Nunes et al.
Clinical therapeutics, 31(10), 2258-2271 (2009-11-20)
Nebicapone is a reversible catechol-O-methyltransferase (COMT) inhibitor. Coadministration of a COMT inhibitor with levodopa and a dopa-decarboxylase inhibitor (carbidopa or benserazide) increases levodopa exposure and its therapeutic effect. The primary objective of this study was to investigate the effect of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico